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Introduction: Chilblains or perniosis is an acrally located cutaneous eruption that occurs with exposure to cold.
Chilblains can be classified into primary and secondary forms. The primary or idiopathic form is not associated with an
underlying disease and is clinically indistinguishable from the secondary form. The secondary form is associated with
an underlying condition such as connective tissue disease, monoclonal gammopathy, cryoglobulinemia, or chronic
myelomonocytic leukemia. Histopathology cannot accurately help distinguish the primary from secondary forms of
chilblains. This article will raise the awareness of chilblains by presenting two unusual case reports of chilblains in men
from Southern California with discussion of the appropriate evaluation and treatment of this condition.
Case presentations: Case 1
A 56-year-old Caucasian man presented in January to a Southern California primary care clinic with a report of tingling
and burning in both feet, followed by bluish discoloration and swelling as well as blistering. He had no unusual cold
exposure prior to the onset of his symptoms. He had a history of “white attacks” in his hands consistent with Raynaud’s
phenomenon. His symptoms gradually resolved over a 3-week period.
Case 2
A 53-year-old Caucasian man also presented to a Southern California clinic in January with a 3-week history of painful
tingling in his toes, and subsequent purplish-black discoloration of the toes in both feet. His symptoms occurred 1
week after a skiing trip. He had partial improvement with warming measures. His symptoms resolved 2 weeks after his
initial presentation.
Conclusions: Chilblains is a relatively uncommon entity in warmer climates but can present during the winter
months. Primary care providers in warmer climates such as Southern California in the USA may be unfamiliar with
its presentation. It can be diagnosed clinically by the appearance of typical lesions during the cold damp season.
Through a thorough history, physical examination and selected laboratory evaluation, underlying connective
tissue disease or a mimic such as vasculitis or cutaneous leukemia can be excluded.
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Chilblains or perniosis is an acrally located eruption
that occurs with exposure to cold. The lesions may be
erythematous or purplish in color and may be either
macular or papular. Chilblains may be primary or idio-
pathic, or secondary to an underlying connective tissue
disease (CTD), monoclonal gammopathy or cryoglobu-
linemia. The differential diagnosis includes vasculitis,
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unless otherwise stated.(SLE), and emboli. A skin biopsy can help exclude these
other diagnoses, but the histopathology of chilblains is
nonspecific. The histopathologic findings include an
inflammatory infiltrate usually extending through the
dermis with associated edema, and may be concentrated
in a perieccrine distribution. The epidermis may show
necrotic keratinocytes. Cribier et al. studied biopsy speci-
mens from patients with chilblains to determine if there
are characteristic histopathologic features that distinguish
primary chilblains from lupus erythematosus [1]. They
concluded that it is not always possible to distinguish
between idiopathic chilblains and lupus erythematosus
based on histopathologic findings alone. However, lackl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of laboratory data for cases 1 and 2
Laboratory evaluation Normal range Case 1 Case 2
Antinuclear Ab < 1:40 titer 1:160 <1:40




C3 71–141mg/dL 133 120
C4 12–34mg/dL 49 22
Rheumatoid factor <25IU/mL <10 <10
C-reactive protein <0.8mg/dL 0.3 0.3
C-ANCA <1:20 titer <1:20 <1:20
P-ANCA <1:20 titer <1:20 <1:20
Proteinase-3 Ab <21U <21 <21
Myeloperoxidase Ab <21U <21 <21
Cardiolipin IgG <15GPL <15 <15
Cardiolipin IgM <12.5MPL <12.5 <12.5
Cardiolipin IgA <12APL <12 <12
Beta-2-Glycoprotein IgG ≤20SGU <9 <9
Beta-2-Glycoprotein IgM ≤20SMU <9 <9
Beta-2-Glycoprotein IgA ≤20SAU <9 <9
Anti- SM Ab <20U <20 <20
Anti- RNP AB <20U <20 <20
Anti- SSA Ab <20U <20 <20
Anti- SSB Ab <20U <20 <20










Hepatitis B surface Negative Negative Negative
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characteristic of lupus erythematosus [1].
We present two cases of chilblains from Southern
California and a review of the literature. The first case is
an example of secondary chilblains. The second case is
an example of idiopathic chilblains.
Case presentations
Case 1
A 56-year-old Caucasian man, a non-smoker, presented
in late January (mid-winter) reporting that 2 weeks prior
he suddenly developed tingling and burning in the toes
of both feet. He then developed bluish discoloration and
swelling, along with some blistering on the dorsum of
his toes (Figure 1). He did not recall any precipitating
events or unusual cold exposure. Over the previous 2
weeks the blistering and swelling gradually subsided and
at the time of presentation only the bluish discoloration
in his toes remained. Within 3 weeks his toes returned
to their normal appearance.
Of note, he reports a history of “white-attacks” of the
fingers upon cold exposure since early childhood (con-
sistent with Raynaud’s phenomenon). He has no known
history of CTD or autoimmune disease.
Initial laboratory findings were significant for an anti-
nuclear antibody (ANA) positive at 1:160 ratio. He was
sent to the rheumatology clinic for further evaluation.
Follow-up studies included a complement component 4
(C4) level of 49 (12 to 34mg/dL), a 50% hemolytic
complement (CH50) of 154 (60 to 144 CAE units), and
a deoxyribonuclease (DNase-B) antibody of 232 (0 to
120U/mL). The remainder of the hypercoagulable and
vasculitic work-up was negative (Table 1), as were an
echocardiogram and abdominal ultrasound to rule out a
source for an embolic process.Figure 1 Photo taken by patient within 1 week of onset of
symptoms demonstrating erythematous and purplish
maculopapular lesions with vesicle formation in the toes.
antigen
Hepatitis C Ab Negative Negative Negative
Rapid plasma reagin (RPR) Nonreactive Nonreactive Nonreactive
Abbreviations: Ab, antibody; Anti-dsDNA Ab EIA, anti-double-stranded
DNA antibody by enzyme-linked immunosolvent assay; Anti-RNP Ab,
antiribonucleoprotein antibodies; Anti-SM Ab, anti-Smith antibodies; Anti-SSA,
anti-Sjögren’s Syndrome A antibody; Anti-SSB, anti-Sjögren’s Syndrome B
antibody; C3, complement component 3; C4, complement component 4;
C-ANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CH50, 50%
hemolytic complement; Cryocrit, percent of packed cryoglobulins; Ig,
immunoglobulin; P-ANCA, perinuclear antineutrophil cytoplasmic
antibodies. Bold values are abnormal.Over a 1-year follow-up period, he experienced several
episodes of Raynaud’s attacks in both his hands and feet.
These episodes were characterized by red and painful
digits, sometimes with swelling, but without vesicles or
ulcers. He did not notice an association with the cold,
but the episodes resolved within hours with warming
measures.
Figure 2 Images show a punch biopsy from the left plantar great
toe with the histopathologic findings of a dense superficial and
deep perivascular lymphocytic infiltrate; extravasated red blood
cells are present in the upper dermis but there is no evidence
of vasculitis.
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A 53-year-old Caucasian man, a non-smoker who works
as an auto dealer, also presenting in late January, reported
that 3 weeks prior he developed painful tingling in his
toes, and subsequent development of purple/black
discoloration on his toes in both feet. He had been on a
skiing trip approximately a week prior to the start of
these symptoms. Other than some fatigue, he did not
report any other symptoms, and had no other past
medical history. On examination, he had flat purple/red
lesions on the plantar aspects of the first through third
toes, bilaterally. The lesions improved, but did not
completely disappear with warming. The remainder of
the examination was normal. His lesions resolved within 2
weeks of evaluation. There was no reported long-term
follow up for this patient.
The results of his laboratory examination were normal,
with an erythrocyte sedimentation rate (ESR) of 5. ANA,
rheumatoid factor, antiphospholipid antibodies, and cryo-
globulins were negative (Table 1).
An echocardiogram and abdominal ultrasound did not
reveal any source of embolism.
Punch biopsy revealed superficial and deep perivascular
lymphocytic infiltrates with focal dermal hemorrhage and
mild dermal edema (Figure 2a and 2b). No vasculitis was
seen. Diagnosis was consistent with chilblains/perniosis.
Discussion
Chilblains, or perniosis, manifests as cold-induced inflam-
matory cutaneous lesions. It can easily be mistaken for
vasculitis or an embolic event; and, as illustrated by our
two cases, can be idiopathic or a secondary phenomenon
related to an underlying CTD, typically SLE. A form of
familial lupus chilblains exists, associated with a TREX1
gene mutation, mostly in Asian populations [2-4].
The exact pathogenesis of chilblains is unknown. The
process is generally described as a vasculopathy whereby
there is disruption of normal neurovascular responses to
dermal temperature changes. It has been suggested that
patients with chilblains have persistent or prolonged
cold-induced vasoconstriction leading to hypoxemia and
a subsequent secondary inflammatory reaction [5].
There are no pathognomonic histological findings for
idiopathic chilblains, but many studies describe superficial
and deep perivascular lymphocytic infiltrates, with vessel
wall and papillary dermal edema [1,5-7]. It has been
suggested that idiopathic chilblains may be distinguished
from secondary lesions seen in lupus by the presence of
spongiosis, perieccrine inflammation, and dermal edema
[1] in idiopathic lesions, whereas vacuolation of basal cells
is more commonly seen in lupus erythematosus lesions.
Idiopathic chilblains is frequently seen in cold, damp
areas of Western Europe (air humidity appears to enhance
air conductivity of cold); however, an increasing numberof cases are being reported in coastal areas of North
America [5]. Cases typically present during the cold
season of late winter to early spring. Attacks can, however,
be precipitated by other types of cold exposure. Cases
have been reported with use of cold therapy systems,
which are used after some orthopedic procedures [8].
Lesions are almost always seen within a few hours of
exposure to nonfreezing, damp conditions. Typically,
they manifest as painful erythematous or purple lesions
with associated swelling or itching. Overlaying erosions,
ulcerations, or blisters may also be seen. Chilblain lesions
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Other locations include the ear, nose, thighs, and buttocks
[5]. In general, a female predominance is seen and may be
associated with a low body mass index, although lesions
are not uncommonly observed in men and children.
Female gender is strongly associated with underlying
CTD, especially SLE. The results of laboratory evaluation
of idiopathic chilblains are usually normal, although an
elevated ESR has been observed in some cases [5].
Secondary chilblains can present as a cutaneous fea-
ture of many conditions such as lupus (most commonly),
Behcet's disease, monoclonal gammopathy, cryoglobuline-
mia, chronic myelomonocytic leukemia, antiphospholipid
syndrome, and other CTDs. There have even been cases
of tumor necrosis factor inhibitor-induced lupus chilblains
[7,9]. Lesions present similarly to idiopathic chilblains,
although persistence of lesions beyond the cold seasons is
more common with secondary chilblains [10]. Pathogen-
esis is probably similar to that of idiopathic chilblains,
involving an exaggerated vasoconstrictive response with
subsequent hypoxemia and inflammation. However, hy-
perviscosity may play more of a role in the development
of secondary lesions. Hypergammaglobulinemia and auto-
antibodies, frequently seen with CTD, may play a role in
the development of these lesions, but their exact patho-
physiological relevance is not known [11]. One epidemio-
logic study of chilblains suggests advanced age, female
gender, persistence of the disorder beyond the cold season,
hypergammaglobulinemia, and autoantibody positivity are
suggestive of secondary chilblains [10].
The diagnosis can usually be made clinically by the
appearance of typical lesions during the cold damp
seasons. Idiopathic chilblains is, however, a diagnosis of
exclusion, and an underlying CTD, or a mimic, such as
vasculitis or cutaneous leukemia [12], must be considered.
A thorough history and physical examination should be
performed to evaluate for the presence of systemic disease.
Initial laboratory evaluation should include: a complete
blood count, ANA and antiphospholipid antibody profiles,
cryoglobulins, and serum protein electrophoresis. Biopsy
should be considered for treatment-resistant cases. Typ-
ical lesions in a person with a known CTD or Raynaud’s
can help to make the diagnosis of secondary chilblains.
Again, a biopsy may need to be considered for lesions
resistant to warming measures because it is important
to distinguish chilblains from vasculitis, which requires
immunosuppressive therapy.
Treatment of chilblains is focused on keeping the
affected area warm, and occasionally using vasodilator
agents such as calcium-channel blockers. At least two small
placebo-controlled studies showed rapid improvement of
symptoms with use of extended-release nifedipine 20mg,
taken three times daily [13,14]. Calcium-channel blockers
may also play a role in prevention of recurrent or chroniclesions [7,11]. Regardless of therapy, symptoms generally
resolve within days to months, although chronic, waxing
and waning lesions can develop with persistent cold expos-
ure. Secondary chilblains may have a more chronic course,
and there have been cases of response to corticosteroids
(systemic and topical) and mycophenolate mofetil [5,11].
Data on the use of anti-malarial medications, such as
hydroxychloroquine, for both idiopathic and secondary
lesions are relatively limited. Results from small retro-
spective studies are conflicting [15]. Some studies suggest
that while hydroxychloroquine is helpful for many symp-
toms of CTD, it is not necessarily helpful in treating
chilblain lesions [5,11].
Conclusions
In this series, we present two cases of chilblains seen in
the winter months in Southern California. One case is
purely idiopathic, whereas the other is more consistent
with a secondary phenomenon related to the patient’s
history of Raynaud’s and an underlying undifferentiated
CTD. In both cases, lesions responded well to warming
measures alone. This condition needs to be recognized
even in typically warmer climates, and screening for an
underlying systemic disease should be done, especially in
treatment-resistant cases.
Consent
Written informed consent was obtained from the patients
for publication of this case report and accompanying
images. Copies of the written consents are available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RG was a major contributor in writing the manuscript, and made the
diagnosis for Case 1. AA contributed to the manuscript and interpretation of
patient data, and initially evaluated the patient for Case 1. AP made the
diagnosis for the patient in Case 2 and contributed to the writing of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to acknowledge the patient presented in Case 1 for providing
us with the photograph showing his chilblain lesions. We would also like to
thank Dr Richard A. Rison for his editorial assistance and recommendations.
Author details
1UCLA Department of Rheumatology, 2020 Santa Monica Blvd., Suite 540,
Santa Monica, CA 90403, USA. 2UCLA Department of Family Medicine Family
Health Center, 1920 Colorado Avenue, Santa Monica, CA 90404, USA. 3UCLA
Division of Dermatology, 10833 Le Conte Avenue, CHS 52-121, Los Angeles,
CA 90095, USA.
Received: 25 March 2014 Accepted: 1 September 2014
Published: 22 November 2014
References
1. Cribier B, Djeridi N, Peltre B, Grosshans E: A histologic and
immunohistochemical study of chilblains. J Am Acad Dermatol 2001,
45:924–929.
Gordon et al. Journal of Medical Case Reports 2014, 8:381 Page 5 of 5
http://www.jmedicalcasereports.com/content/8/1/3812. Sugiura K, Takeichi T, Kono M, Ito Y, Ogawa Y, Muro Y, Akiyama M: Severe
chilblain lupus is associated with heterozygous missense mutations of
catalytic amino acids or their adjacent mutations in the exonuclease
domains of 3'-repair exonuclease 1. J Invest Dermatol 2012, 132:2855–2857.
3. Abe J, Izawa K, Nishikomori R, Awaya T, Kawai T, Yasumi T, Hiragi N, Hiragi T,
Ohshima Y, Heike T: Heterozygous TREX1 p.Asp18Asn mutation can cause
variable neurological symptoms in a family with Aicardi–Goutières
syndrome/familial chilblain lupus. Rheumatology 2012, 52:406–408.
4. Gunther C, Meurer M, Stein A, Viehweg A, Lee-Kirsch MA: Familial chilblain
lupus – A monogenic form of cutaneous lupus erythematosus due to a
heterozygous mutation in TREX1. Dermatology 2009, 219:162–166.
5. Prakash S, Weisman MH: Idiopathic chilblains. Am J Med 2009, 122:1152–1155.
6. Crowson AN, Margo CM: Idiopathic Perniosis and Its Mimics: A clinical
and histological study of 28 cases. Hum Pathol 1997, 28:478–484.
7. Sifuentes Giraldo WA, Ahijón Lana M, García Villanueva MJ, González Garcíá
C, Vásquez Diaz M: Chilblain lupus induced by TNF-alpha antagonists: a
case report and literature review. Clin Rheumatol 2012, 31:563–568.
8. King JM, Plotner AN, Adams BB: Perniosis induced by a cold-therapy
system. Arch Dermatol 2012, 148(9):1101–1102.
9. Richez C, Dumoulin C, Schaeverbeke T: Infliximab induced chilblain lupus
in a patient with rheumatoid arthritis. J Rheumatol 2005, 32:760–761.
10. Takci Z, Vahaboglu G, Eksioglu H: Epidemiological patterns of perniosis,
and its association with systemic disorder. Clin Exp Dermatol 2012,
37:844–849.
11. Hedrich CM, Fiebig G, Hauck FH, Sallmann S, Hahn G, Pfeiffer C, Heubner G,
Lee-Kirsch MA, Gahr M: Chilblain lupus erythematosus: a review of literature.
Clin Rheumatol 2008, 27:949–954.
12. Al-Niaimi F, Chadha M, Cox N: Leukaemia cutis presenting as digital and
chilblain-like perniosis. EDJ 2010, 20:836–837.
13. Rustin MHA: Nifedipine in the treatment of chilblains. Br Med J 1986,
293:923–924.
14. Goette D: Chilblains (Perniosis). J Am Acad Dermatol 1990, 23:257–262.
15. Yang X, Perez OA, English JC 3rd: Successful treatment of perniosis with
hydroxychloroquine. J Drugs Dermatol 2010, 9(10):1242–1246.
doi:10.1186/1752-1947-8-381
Cite this article as: Gordon et al.: Chilblains in Southern California: two
case reports and a review of the literature. Journal of Medical Case
Reports 2014 8:381.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
